专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006044989A1 DEVICES AND METHODS FOR DELIVERY OF PIMECROLIMUS AND OTHER THERAPEUTIC AGENTS 审中-公开
标题翻译：用于输送PIMECROLIMUS和其他治疗药物的装置和方法
公开(公告)号：WO2006044989A1
公开(公告)日：2006-04-27
申请号：PCT/US2005/037658
申请日：2005-10-17
申请人： AVANTEC VASCULAR CORPORATION , BHAT, Vinayak, D. , YAN, John , SHAH, Ashok, A.
发明人： BHAT, Vinayak, D. , YAN, John , SHAH, Ashok, A.
IPC分类号： A61F2/06
CPC分类号： A61L31/16 , A61F2/86 , A61F2250/0067 , A61L2300/416 , A61L2300/45 , A61L2300/608
摘要： The present invention is directed to an intracorporeal device, such as a stent, and methods for reducing, inhibiting, or treating restenosis and hyperplasia by introducing an intracorporeal device into the patient's body with a coating of a primary therapeutic agent, pimecrolimus, which is configured to be released in a sustained or controlled manner. The device may be a structure or scaffolding with the source of the therapeutic agent proximate to the structure or scaffolding for release of the therapeutic agent into the patient's body. The device is suitable for use in a patient's vasculature, particularly the patient's coronary, carotid and peripheral arteries.
摘要翻译：本发明涉及体内装置，例如支架，以及用于通过将主体治疗剂吡美罗莫司（pimecrolimus）的涂层引入患者体内来减少，抑制或治疗再狭窄和增生的方法以持续或受控的方式释放。该装置可以是具有靠近结构或支架的治疗剂源的结构或支架，用于将治疗剂释放到患者体内。该装置适用于患者的脉管系统，特别是患者的冠状动脉，颈动脉和外周动脉。

2. 发明申请

WO2004010900A1 DEVICES DELIVERING THERAPEUTIC AGENTS AND METHODS REGARDING THE SAME 审中-公开
标题翻译：递送治疗药物的装置及其相关方法
公开(公告)号：WO2004010900A1
公开(公告)日：2004-02-05
申请号：PCT/US2003/020492
申请日：2003-06-27
申请人： AVANTEC VASCULAR CORPORATION , BHAT, Vinayak, D. , YAN, John
发明人： BHAT, Vinayak, D. , YAN, John
IPC分类号： A61F2/06
CPC分类号： A61F2/915 , A61F2/91 , A61F2002/91533 , A61F2230/0054 , A61F2250/0067
摘要： Devices and methods for reducing, inhibiting, or treating restenosis and hyperplasia after intravascular intervention are provided. In particular, the present invention provides luminal prosthesis (13), which allow for sustained or controlled release of at least one therapeutic capable agent (28) with increase efficacy to selected locations within a patient's vasculature to reduce stenosis. An intraluminal prosthesis may comprise an expandable structure and a source adjacent the expandable structure for releasing the therapeutic agent (28) into a body lumen to reduce smooth muscle cell proliferation.
摘要翻译：提供减少，抑制或治疗血管内干预后再狭窄和增生的装置和方法。特别地，本发明提供了腔体假体（13），其允许持续或控制释放至少一种治疗能力的药剂（28），其对患者血管系统内的选定位置的功效增加以减少狭窄。腔内假体可以包括可扩张结构和邻近可扩张结构的源，用于将治疗剂（28）释放到体腔中以减少平滑肌细胞增殖。

3. 发明申请

WO2005051229A2 DEVICES DELIVERING THERAPEUTIC AGENTS AND METHODS REGARDING THE SAME 审中-公开
标题翻译：递送治疗药物的装置及其相关方法
公开(公告)号：WO2005051229A2
公开(公告)日：2005-06-09
申请号：PCT/US2004/039062
申请日：2004-11-19
申请人： AVANTEC VASCULAR CORPORATION , BHAT, Vinayak D. , YAN, John
发明人： BHAT, Vinayak D. , YAN, John
IPC分类号： A61F
CPC分类号： A61L31/16 , A61F2250/0067 , A61L27/54 , A61L2300/414 , A61L2300/416
摘要： Devices and methods for reducing, inhibiting, or treating restenosis and hyperplasia after intravascular intervention are provided. In particular, the present invention provides luminal prostheses which allow for sustained or controlled release of at least one therapeutic capable agent with increased efficacy to selected locations within a patient's vasculature to reduce restenosis. An intraluminal prosthesis may comprise an expandable structure and a source adjacent the expandable structure for releasing the therapeutic capable agent into a body lumen to reduce smooth muscle cell proliferation.
摘要翻译：提供了用于减少，抑制或治疗血管内干预后再狭窄和增生的装置和方法。特别地，本发明提供了腔内假体，其允许至少一种具有治疗能力的药剂的持续或受控释放，其对患者脉管系统内的选定位置具有增加的功效以减少再狭窄。腔内假体可以包括可扩张结构和邻近可扩张结构的源，用于将可治疗能力的药剂释放到体腔中以减少平滑肌细胞增殖。

4. 发明申请

WO2010040064A1 MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE 审中-公开
标题翻译： MACROCYCLIC LACTONE化合物及其使用方法
公开(公告)号：WO2010040064A1
公开(公告)日：2010-04-08
申请号：PCT/US2009/059396
申请日：2009-10-02
申请人： ELIXIR MEDICAL CORPORATION , YAN, John , ZHENG, Xiaoxia , BHAT, Vinayak, D.
发明人： YAN, John , ZHENG, Xiaoxia
IPC分类号： A61F2/06
CPC分类号： A61K31/436 , A61K45/06 , A61L29/041 , A61L29/148 , A61L29/16 , A61L31/048 , A61L31/148 , A61L31/16 , A61L2300/41 , A61L2300/416 , A61L2300/42 , A61L2300/426
摘要： The present invention provides a device for intracorporeal use including an implant or a temporary device and at least one source of a compound myolimus, or a derivative thereof. The present invention also provides a method of inhibiting cell proliferation by local administration of a therapeutically effective amount of a compound myolimus, or a derivative thereof. Further included in the present invention is a method of treating an ophthalmic condition or disease by administering a therapeutically effective amount of a compound myolimus, or a derivative thereof.
摘要翻译：本发明提供一种用于体内使用的装置，包括植入物或临时装置，以及至少一种化合物myolimus或其衍生物的来源。本发明还提供了一种通过局部施用治疗有效量的化合物myolimus或其衍生物来抑制细胞增殖的方法。本发明还包括通过施用治疗有效量的化合物肌醇或其衍生物来治疗眼科疾病或疾病的方法。

5. 发明申请

WO2003009778A2 METHODS AND DEVICES FOR DELIVERY OF THERAPEUTIC CAPABLE AGENTS WITH VARIABLE RELEASE PROFILE 审中-公开
标题翻译：用于输送具有可变释放特征的治疗药物的方法和装置
公开(公告)号：WO2003009778A2
公开(公告)日：2003-02-06
申请号：PCT/US2002/023830
申请日：2002-07-25
申请人： AVANTEC VASCULAR CORPORATION , SIRHAN, Motasim , YAN, John
发明人： SIRHAN, Motasim , YAN, John
IPC分类号： A61F
CPC分类号： A61F2/91 , A61F2/915 , A61F2002/91533 , A61F2002/91558 , A61F2002/91583 , A61F2230/0054 , A61F2250/0067 , A61F2250/0068 , A61L31/16 , A61L2300/416
摘要： The present invention provides improved stents and other prostheses for delivering substances to vascular and other luminal and intracorporeal environments. In particular, the present invention provides for therapeutic capable agent stents with a variable release profile along a length of the stent.
摘要翻译：本发明提供了用于将物质递送到血管和其他腔内和体内环境的改进的支架和其他假体。特别地，本发明提供具有沿着支架长度的可变释放曲线的治疗能力的支架。

6. 发明申请

WO2012047813A1 MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE 审中-公开
标题翻译： MACROCYCLIC LACTONE化合物及其使用方法
公开(公告)号：WO2012047813A1
公开(公告)日：2012-04-12
申请号：PCT/US2011/054637
申请日：2011-10-03
申请人： ELIXIR MEDICAL CORPORATION , YAN, John , ZHENG, Xiaoxia , BHAT, Vinayak, D.
发明人： YAN, John , ZHENG, Xiaoxia , BHAT, Vinayak, D.
IPC分类号： A61K31/44 , A61F2/00
CPC分类号： A61L31/16 , A61K31/436 , A61K45/06 , A61L29/06 , A61L29/148 , A61L29/16 , A61L31/06 , A61L31/08 , A61L31/148 , C08L67/04 , A61K2300/00
摘要： The present disclosure provides a device for intracorporeal use which comprises an implant or a temporary device and at least one source of myolimus or a derivative thereof. The present disclosure also provides a method of inhibiting cell proliferation, inflammation or cytokine production by systemic or local administration of a therapeutically effective amount of myolimus or a derivative thereof. Further included in the present disclosure is a method of treating an ophthalmic condition or disease by administering a therapeutically effective amount of myolimus or a derivative thereof.
摘要翻译：本公开提供了一种用于体内使用的装置，其包括植入物或临时装置和至少一种肌醇来源或其衍生物。本公开还提供了通过全身或局部施用治疗有效量的肌醇酰胺或其衍生物来抑制细胞增殖，炎症或细胞因子产生的方法。本公开内容中还包括通过施用治疗有效量的肌醇酰胺或其衍生物来治疗眼科疾病或疾病的方法。

7. 发明申请

WO2008033956A2 MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE 审中-公开
标题翻译： MACROCYCLIC LACTONE化合物及其使用方法
公开(公告)号：WO2008033956A2
公开(公告)日：2008-03-20
申请号：PCT/US2007/078317
申请日：2007-09-12
申请人： ELIXIR MEDICAL CORPORATION , YAN, John , ZHENG, Xiaoxia , BHAT, Vinayak D.
发明人： YAN, John , ZHENG, Xiaoxia , BHAT, Vinayak D.
IPC分类号： A61K31/787
CPC分类号： A61K31/787 , A61L27/34 , A61L27/54 , A61L29/085 , A61L29/16 , A61L31/10 , A61L31/16 , A61L2300/416 , A61K2300/00
摘要： The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula (I) wherein R 1 , R 2 , R 3 , R 5 , R 6 and R 8 are each independently a member selected from the group consisting of H, C 1-6 alkyl and OH; R 4 , R 7 and R 9 are each independently selected from the group consisting of C 1-6 alkoxy and OH; R 10 is a member selected from the group consisting of H, -OH, -OP(O)Me 2 , (II) -O-(CH 2 ) n -OH and -O-(CH 2 ) m -O-(CH 2 ) o - CH 3 , wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L 1 and L 4 are independently selected from the group consisting of: (III) each of L and L3 are independently selected from the group consisting of: (IV) salts, hydrates, isomers, metabolites and prodrugs thereof.
摘要翻译：本发明提供药物组合物，其包含药学上可接受的赋形剂和式（I）化合物，其中R 1，R 2，R 3， >，R 5，R 6和R 8各自独立地是选自H，C 1〜 6烷基和OH; R 4，R 7和R 9各自独立地选自C 1-6 - 烷氧基和OH; R 10是选自H，-OH，-OP（O）Me 2 2，（II）-O-（CH 2） -OH和-O-（CH 2）2 - （CH 2）n - （CH 2）n - 其中下标n和m各自独立地为2至8，下标o为1至6; L 1和L 4各自独立地选自：（III）L和L3各自独立地选自：（IV）盐，水合物，异构体，代谢物和前药。

8. 发明申请

WO2003037223A1 APPARATUS AND METHODS FOR VARIABLY CONTROLLED SUBSTANCE DELIVERY FROM IMPLANTED PROSTHESES 审中-公开
标题翻译：用于变体物理输送的装置和方法
公开(公告)号：WO2003037223A1
公开(公告)日：2003-05-08
申请号：PCT/US2002/034350
申请日：2002-10-25
申请人： AVANTEC VASCULAR CORPORATION , SIRHAN, Motasim , YAN, John
发明人： SIRHAN, Motasim , YAN, John
IPC分类号： A61F2/06
CPC分类号： A61L27/54 , A61F2/91 , A61F2/915 , A61F2/95 , A61F2002/91533 , A61F2002/91558 , A61F2002/91583 , A61F2230/0054 , A61F2250/0067 , A61F2250/0068 , A61L31/16 , A61L2300/416 , A61L2300/602
摘要： The present invention provides improved stents and other prostheses for delivering substances to vascular and other luminal and intracorporeal environments. In particular, the present invention provides luminal prostheses (13) which allow for programmed and controlled substance delivery protocols for a variety of purposes. The prostheses (13) comprised a scaffold which is implanted within the body lumen and a substance reservoir present over at least a portion of the scaffold. Usually, a rate-controlling element will be formed over the substance-containing reservoir to provide for a number of different substance release characteristics.
摘要翻译：本发明提供了用于将物质递送到血管和其他腔内和体内环境的改进的支架和其他假体。特别地，本发明提供了腔体假体13，其允许用于各种目的的编程和受控物质递送方案。假体13包括植入体腔内的支架和存在于支架的至少一部分上的物质储存器。通常，在含物质储存器上形成速率控制元件以提供许多不同的物质释放特性。

9. 发明申请

WO2003009779A2 DELIVERY OF THERAPEUTIC CAPABLE AGENTS 审中-公开
标题翻译：交付治疗药物
公开(公告)号：WO2003009779A2
公开(公告)日：2003-02-06
申请号：PCT/US2002/023922
申请日：2002-07-25
申请人： AVANTEC VASCULAR CORPORATION , SIRHAN, Motasim , YAN, John
发明人： SIRHAN, Motasim , YAN, John
IPC分类号： A61F
CPC分类号： A61F2/91 , A61F2/915 , A61F2002/91533 , A61F2002/91558 , A61F2002/91583 , A61F2230/0054 , A61F2250/0067 , A61F2250/0068 , A61L31/16 , A61L2300/416
摘要： The present invention provides improved stents and other prostheses for delivering substances to vascular and other luminal and intracorporeal environments. In particular, the present invention provides for therapeutic capable agent eluting stents with minimized undesirable loss of the therapeutic capable agent during expansion of the stent.
摘要翻译：本发明提供了用于将物质递送到血管和其他腔内和体内环境的改进的支架和其他假体。特别地，本发明提供了治疗能力洗脱支架，其在支架扩张期间具有可治疗能力的药剂的最小化不希望的损失。

10. 发明申请

WO2009114010A1 MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE 审中-公开
标题翻译： MACROCYCLIC LACTONE化合物及其使用方法
公开(公告)号：WO2009114010A1
公开(公告)日：2009-09-17
申请号：PCT/US2008/056501
申请日：2008-03-11
申请人： ELIXIR MEDICAL CORPORATION , YAN, John , ZHENG, Xiaoxia , BHAT, Vinayak D.
发明人： YAN, John , ZHENG, Xiaoxia , BHAT, Vinayak D.
IPC分类号： A01N43/04 , A61K31/70
CPC分类号： A61K31/70 , A61K31/436
摘要： The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula (I) wherein R 1 , R 2 , R 3 , R 5 , R 6 , R 8 , M 1 , M 2 , M 3 , M 4 , M 5 , M 6 and M 7 are each independently a member selected from the group consisting of H, C 1-6 alkyl, OH and C 1-6 hydroxyalkyl; R 4 , R 7 and R 9 are each independently selected from the group consisting of C 1-6 alkoxy and OH; R 10 is a member selected from the group consisting of H, -OH, -OP(O)Me 2 , (II), (III), -O-(CH 2 ) n -OH and -O-(CH 2 ) m -O-(CH 2 ) o -CH 3 , wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L 1 and L 4 are independently selected from the group consisting of (IV) and (V) wherein each M 8 is independently a member selected from the group consisting Of C 1-6 alkyl, OH and C1-6 hydroxyalkyl; each of L 2 and L 3 are independently selected from the group consisting of (VI), (VII) and (VIII); and salts, hydrates, isomers, metabolites, N-oxides and prodrugs thereof.
摘要翻译：本发明提供包含药学上可接受的赋形剂和式（I）化合物的药物组合物，其中R 1，R 2，R 3，R 5，R 6，R 8，M 1，M 2，M 3，M 5，M 6和M 7各自独立选自H，C 1-6烷基，OH和C 1-6羟基烷基的成员; R 4，R 7和R 9各自独立地选自C 1-6烷氧基和OH; R 10是选自H，-OH，-OP（O）Me 2，（II），（III），-O-（CH 2）n -OH和-O-（CH 2）m O-（CH 2））o-CH3，其中下标n和m各自独立地为2至8，下标o为1至6; L1和L4各自独立地选自（IV）和（V），其中每个M8独立地是选自C1-6烷基，OH和C1-6羟基烷基的成员; L2和L3各自独立地选自由（VI），（VII）和（VIII）组成的组。及其盐，水合物，异构体，代谢物，N-氧化物和前药。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式